Repros’ Androxal Primed For NDA Submission, But Outcomes Study Looms
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The testosterone drugmaker is confident that Androxal can gain approval and is on track to submit a filing with FDA this year, but a cardiovascular outcomes study is still on the table.